Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474539 | 0.91 | JAK3 (0.49) | CA2CA12CA1CA9NTRK1 | |
| SCHEMBL1474651 | 0.87 | CCNT1 (0.47) | CA2CA12CA1CA9NTRK1 | |
| SCHEMBL3114861 | 0.84 | ALK (0.55) | NTRK1CDK9CDK5AURKAAURKB | |
| SCHEMBL1474737 | 0.84 | JAK3 (0.55) | NTRK1CCNT1CDK1CCNB1CDK2 | |
| SCHEMBL1474879 | 0.82 | BRD4 (0.42) | NTRK1CDK1CDK2CDK5AURKA | |
| SCHEMBL4003373 | 0.82 | AURKA (0.46) | CA2CA12CA1CA9NTRK1 | |
| SCHEMBL1475976 | 0.81 | CDK1 (0.52) | NTRK1CCNT1CCNB2CCNE2CDK1 | |
| SCHEMBL1474000 | 0.80 | CDK2 (0.49) | CA2CA12CA1CA9NTRK1 | |
| SCHEMBL1474787 | 0.79 | JAK3 (0.51) | CA2CA12CA1CA9NTRK1 | |
| SCHEMBL1474881 | 0.79 | INSR (0.42) | NTRK1CDK1CDK2CDK5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CA2 4550/4885CA12 4660/4885CA1 4805/4885 |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | CA2 4714/4885CA12 4622/4885CA1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.